Regencell Bioscience Holdings (RGC) Earnings Analysis
Regencell Bioscience Holdings (RGC) has no confirmed upcoming earnings date. Trailing P/E -421.13.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does RGC next report earnings?
No confirmed upcoming earnings date is currently scheduled for RGC. This page updates as the calendar is published.
RGC earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-06-15 | -0.0107 USD | n/a | n/a | n/a |
| 2025-11-18 | -0.0035 USD | n/a | n/a | n/a |
RGC valuation and analyst view
| Trailing P/E | -421.13 |
|---|---|
| Trailing EPS | -0.01425 USD |
| Price / book | 2425.03 |
| Dividend yield | 0.00% |
| Market cap | 2.99B |
| Analyst consensus | Hold (0 buy / 4 hold / 0 sell) |
Related research pages
Frequently asked questions
When is Regencell Bioscience Holdings (RGC)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for RGC. This page updates as the calendar is published.
Did RGC beat earnings last quarter?
Consensus estimate data was not available for RGC's 2026-06-15 report.
What is RGC's current P/E ratio and EPS?
RGC trades at a trailing P/E of -421.13 on trailing EPS of -0.014254287378272194 USD.
What do analysts rate RGC?
Analyst consensus is "Hold" across 4 ratings (0 strong buy, 0 buy, 4 hold, 0 sell, 0 strong sell).